Skip to main content
Premium Trial:

Request an Annual Quote

Merck Taps PPD as Preferred Provider for Proteomic Biomarker Discovery

NEW YORK, June 22 (GenomeWeb News) - PPD said yesterday that it has been selected as Merck's "preferred provider" for protein biomarker analysis.

 

Under the terms of the agreement, PPD will analyze Merck samples with its proprietary proteomic analysis platform to identify candidate biological markers for its therapeutic business.

 

Additional terms of the agreement were not disclosed.

 

A PPD spokeswoman told GenomeWeb News that the agreement has extended the collaboration to PPD following its acquisition of SurroMed in January, but the relationship with Merck is non-exclusive.

 

SurroMed had an ongoing collaboration with Merck for its biomarker discovery services. "We had a relationship and we're taking it one step further," the PPD spokesperson said.

 

PPD said that its technology can be used to analyze samples for novel or known biomarkers, in the presence or absence of a drug, in order to evaluate the efficacy of the drug.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.